United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - cilastatin sodium 530 mg - eq. cilastatin 500 mg; imipenem monohydrate 530 mg - eq. imipenem 500 mg - powder for solution for infusion - 500 mg - 500 mg - cilastatin sodium; imipenem monohydrate 530 mg - imipenem and enzyme inhibitor

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cilastatin sodium 530.7mg equivalent to 500 mg cilastatin; imipenem monohydrate 530.1mg equivalent to 500 mg imipenem - powder for injection - 500mg/500mg - active: cilastatin sodium 530.7mg equivalent to 500 mg cilastatin imipenem monohydrate 530.1mg equivalent to 500 mg imipenem excipient: sodium bicarbonate - indicated for the treatment of the following infections due to susceptible organisms: · intra-abdominal infections · lower respiratory tract infections · gynaecological infections · septicaemia · genitourinary tract infections · bone and joint infections · skin and soft tissue infections · endocarditis indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. the majority of these mixed infections are associated with contamination by faecal flora or flora originating from the vagina, skin and mouth. in these mixed infections, bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, ephalosporins and penicillins. however, bacteroides fragilis is usually susceptible to imipenem and cilastatin combination. imipenem and cilastatin combination has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-g, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment imipenem and cilastatin. imipenem+cilastatin rbx is not indicated for the treatment of meningitis.

United States - English - NLM (National Library of Medicine)

hospira, inc. - imipenem (unii: 71otz9ze0a) (imipenem anhydrous - unii:q20im7he75), cilastatin sodium (unii: 5428wxz74m) (cilastatin - unii:141a6amn38) - imipenem anhydrous 250 mg in 100 ml - imipenem and cilastatin for injection (i.v.) for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of staphylococcus aureus (penicillinase-producing isolates), acinetobacter species, enterobacter species, escherichia coli , haemophilus influenzae , haemophilus parainfluenzae , klebsiella species, serratia marcescens. imipenem and cilastatin for injection (i.v.) is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of enterococcus faecalis , staphylococcus aureus (penicillinase-producing isolates), enterobacter species, escherichia coli , klebsiella species, morganella morganii , proteus vulgaris , providencia rettgeri , pseudomonas aeruginosa. imipenem and cilastatin for injection (i.v.) is indicated for the treatment of intra-abdominal infections caused by susceptible strains of enterococcus faecalis , staphylococcus aureus (penicillinase-producing isolates), staphylococ

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - imipenem (unii: 71otz9ze0a) (imipenem anhydrous - unii:q20im7he75), cilastatin sodium (unii: 5428wxz74m) (cilastatin - unii:141a6amn38) - imipenem anhydrous 250 mg in 20 ml - imipenem and cilastatin for injection, usp (i.v.) for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of staphylococcus aureus (penicillinase-producing isolates), acinetobacter species, enterobacter species, escherichia coli , haemophilus influenzae , haemophilus parainfluenzae , klebsiella species, serratia marcescens . imipenem and cilastatin for injection, usp (i.v.) is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of enterococcus faecalis , staphylococcus aureus (penicillinase-producing isolates), enterobacter species, escherichia coli , klebsiella species, morganella morganii , proteus vulgaris , providencia rettgeri ,

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - cilastatin sodium; imipenem monohydrate -

Canada - English - Health Canada

pfizer canada ulc - cilastatin (cilastatin sodium); imipenem - powder for solution - 500mg; 500mg - cilastatin (cilastatin sodium) 500mg; imipenem 500mg - carbapenems

Canada - English - Health Canada

sterimax inc - cilastatin (cilastatin sodium); imipenem - powder for solution - 250mg; 250mg - cilastatin (cilastatin sodium) 250mg; imipenem 250mg - carbapenems

Canada - English - Health Canada

sterimax inc - cilastatin (cilastatin sodium); imipenem - powder for solution - 500mg; 500mg - cilastatin (cilastatin sodium) 500mg; imipenem 500mg - carbapenems